Download FREE Sample
Overview
Insulin delivery devices refer to medical tools designed to administer insulin in a precise, safe, and convenient manner. Insulin delivery is essential for individuals with type 1 and type 2 diabetes who require insulin therapy as part of their daily disease management. These devices play a crucial role in improving patient adherence, glycemic control, and overall quality of life. Some common types of insulin delivery devices include insulin pens, pumps, injections, and smart automated delivery systems, which provide precise and convenient insulin administration, essential for maintaining glycemic control.
To learn more about this report, download the PDF brochure
Rising prevalence of diabetes fuels demand for self-administered insulin devices
The rising global prevalence of diabetes is a major driver of growth in the insulin delivery device market. According to the International Diabetes Federation (IDF), over 589 million adults were living with diabetes in 2024, and this number is projected to reach 853 million by 2050. This surge is primarily linked to sedentary lifestyles, aging and unhealthy diet patterns, which are more pronounced in low- and middle-income regions, where access to timely diagnosis and treatment remains a challenge.
The rise in the number of diabetes cases necessitates effective management strategies, thereby driving the demand for insulin delivery devices. In particular, the growing adoption of self-administered insulin delivery devices has further contributed to this trend, offering patients greater independence and flexibility in managing their condition. Furthermore, the economic burden of diabetes is substantial, with global health expenditures related to the disease was USD 1 trillion in 2024, as reported by IDF, underscoring the need for efficient and scalable insulin delivery technologies to manage the condition.
Closed-loop integration of insulin delivery with CGM enhances diabetes management
The integration of insulin delivery devices with continuous glucose monitoring (CGM) systems represents a significant advancement in diabetes management, offering benefits for both type 1 and insulin-dependent type 2 diabetes patients. These automated systems enable real-time insulin dosing based on continuous glucose data, enhancing precision and reducing the risk of dangerous highs and lows in blood sugar levels. For individuals with type 1 diabetes who rely on constant insulin administration, this technology provides tighter glycemic control, less variability, and improved day-to-day management. For insulin-dependent type 2 diabetes patients, who may struggle with adherence or complex treatment routines, the automated delivery simplifies therapy, improves consistency, and reduces the need for manual adjustments. According to the research article published in NIH, closed-loop therapy can improve glycemic control more than conventional insulin therapy with CGM in people with type 2 diabetes. Overall, this closed-loop approach eases the daily burden of diabetes care, improves quality of life, and supports better long-term clinical outcomes.
Recent developments in the insulin delivery device market
In the past few months, leading companies have secured FDA clearance for next-generation continuous glucose monitoring and automated insulin delivery solutions, expanding treatment options for both type 1 and type 2 diabetes patients, thereby highlighting rapid innovation in diabetes care technology. These milestones mark a shift toward smarter, more user-friendly devices that improve long-term disease management, for instance:
- In August 2024, Insulet Corporation announced that the FDA has cleared the Omnipod 5 automated insulin delivery system for adults aged 18 years and older with type 2 diabetes. The Omnipod 5 is the first automated insulin delivery system approved in the US for both type 1 andtype 2 diabetes management
- In August 2024, Abbott entered a global partnership with Medtronic to integrate its world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic-s automated insulin delivery (AID) and smart insulin pen systems, enabling CGM-driven automatic insulin adjustments
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global insulin delivery device market comprises several well-established and emerging players, including Medtronic plc; Insulet Corporation; Tandem Diabetes Care, Inc.; Novo Nordisk A/S; Eli Lilly and Company; Sanofi S.A.; Biocon Limited; F. Hoffmann-La Roche Ltd.; and Abbott Laboratories; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| ~8% | |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product Type, Disease Type, and End-user |
| Regional Scope |
|
| Key Companies Mapped | Medtronic plc; Insulet Corporation; Tandem Diabetes Care, Inc.; Novo Nordisk A/S; Eli Lilly and Company; Sanofi S.A.; Biocon Limited; F. Hoffmann-La Roche Ltd.; and Abbott Laboratories; among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Insulin Delivery Device Market Segmentation
This report by Medi-Tech Insights provides thesize of the global insulin delivery device market at theregional- and country-level from 2023 to 2030. The report further segments the market based on product type, disease type, and end-user.
Market Size & Forecast (2023-2030), By Product Type, USD Million
"list-style-type: none">- Insulin Pens
- Reusable Pens
- Disposable Pens
- Insulin Pumps
- Patch Pumps
- Tethered Pumps
- Insulin Pen Needles
- Standard Needles
- Safety Needles
- Insulin Syringes
- Others
Market Size & Forecast (2023-2030), By Disease Type, USD Million
-
- Type 1 Diabetes
- Type 2 Diabetes
Market Size & Forecast (2023-2030), By End-user, USD Million
-
- Hospital
- Clinics
- Homecare Settings
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the insulin delivery device market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the insulin delivery device market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
